SCHEMBL658240

SCHEMBL658240

C1NCNCNCN1.[CH2].[CH2]

nearest known ligand 0.30

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.30
MAPT P10636 1/20 0.30
PDE4A P27815 1/20 0.30
KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17366418 0.93 HIF1A (0.33) HIF1AMAPTPDE4AKDR
SCHEMBL4140732 0.93
SCHEMBL44386 0.93
SCHEMBL5706376 0.86
Methane SCHEMBL16241315 0.86 HIF1A (0.30) HIF1AMAPTPDE4AKDR
Ammonia Solution, Strong SCHEMBL27794312 0.86
SCHEMBL182191 0.84
Ethylene SCHEMBL28083938 0.80
SCHEMBL5616852 0.76 HIF1A (0.50) HIF1AMAPTPDE4AKDR
SCHEMBL5852190 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617761-B2 Process for producing hexahydro 1,3,5-trinitro-1,3,5-triazine and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine PHILLIPS JAMES E (US) 2026-05-05 US claimed
US-20240300906-A1 PROCESS FOR PRODUCING HEXAHYDRO 1,3,5-TRINITRO-1,3,5-TRIAZINE AND OCTAHYDRO-1,3,5,7-TETRANITRO-1,3,5,7-TETRAZOCINE PHILLIPS JAMES E (US) 2024-09-12 US claimed
US-20240228445-A9 PROCESS FOR PRODUCING HEXAHYDRO 1,3,5-TRINITRO-1,3,5-TRIAZINE AND OCTAHYDRO-1,3,5,7-TETRANITRO-1,3,5,7-TETRAZOCINE PHILLIPS JAMES E (US) 2024-07-11 US claimed
US-20240132454-A1 PROCESS FOR PRODUCING HEXAHYDRO 1,3,5-TRINITRO-1,3,5-TRIAZINE AND OCTAHYDRO-1,3,5,7-TETRANITRO-1,3,5,7-TETRAZOCINE PHILLIPS JAMES E (US) 2024-04-25 US claimed
EP-3468923-B1 FLUORESCENT WATER TREATMENT COMPOUNDS AND METHOD OF USE ECOLAB USA INC (US) 2022-10-19 EP claimed
US-20200138787-A1 COSMETIC PRESERVATIVES AS THERAPEUTIC CORNEOSCLERAL TISSUE CROSS-LINKING AGENTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-07 US claimed
US-10292967-B2 Compositions comprising corneoscleral tissue cross-linking agents THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2019-05-21 US claimed
US-20190015388-A1 COMPOSITIONS COMPRISING CORNEOSCLERAL TISSUE CROSS-LINKING AGENTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2019-01-17 US claimed
US-10105350-B2 Cosmetic preservatives as therapeutic corneoscleral tissue cross-linking agents THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-10-23 US claimed
US-20160374992-A1 COSMETIC PRESERVATIVES AS THERAPEUTIC CORNEOSCLERAL TISSUE CROSS-LINKING AGENTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2016-12-29 US claimed
WO-2015138794-A9 COSMETIC PRESERVATIVES AS THERAPEUTIC CORNEOSCLERAL TISSUE CROSS-LINKING AGENTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2016-03-31 WO claimed
US-20120046246-A1 METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) 2012-02-23 US claimed
WO-2010071826-A2 METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-06-24 WO claimed
US-12617761-B2 Process for producing hexahydro 1,3,5-trinitro-1,3,5-triazine and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine PHILLIPS JAMES E (US) 2026-05-05 US disclosed
EP-4073062-B1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) RYVU THERAPEUTICS S A (PL) 2026-04-29 EP disclosed
US-12595238-B2 Process for producing hexahydro 1,3,5-trinitro-1,3,5-triazine and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine PHILLIPS JAMES E (US) 2026-04-07 US disclosed
EP-1117667-B1 BENZOTHIENO[3,2-c]PYRIDINES AS ALPHA2 ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2007-05-30 EP disclosed
EP-1119570-B1 TRICYCLIC DELTA3-PIPERIDINES AS PHARMACEUTICALS JANSSEN PHARMACEUTICA NV (BE) 2004-06-16 EP disclosed
US-6576640-B1 Rapidly penetration into central nervous system; treating noradrenaline deficiency; depression, Parkinson's disease JANSSEN PHARMACEUTICA N.V. (BE) 2003-06-10 US disclosed
EP-0160148-A1 Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper cocatalyst, and a cycloaliphatic amine based promoter EXXON RESEARCH AND ENGINEERING COMPANY (US) 1985-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190015388-A1 COMPOSITIONS COMPRISING CORNEOSCLERAL TISSUE CROSS-LINKING AGENTS SMCHD1, ALDH1A2, CRYAB HIF1A 916/4885MAPT 1897/4885PDE4A 2253/4885
US-10105350-B2 Cosmetic preservatives as therapeutic corneoscleral tissue cross-linking agents COL1A1, COL14A1, COL2A1 HIF1A 859/4885MAPT 2942/4885PDE4A 1264/4885
US-20200138787-A1 COSMETIC PRESERVATIVES AS THERAPEUTIC CORNEOSCLERAL TISSUE CROSS-LINKING AGENTS ALDH1A2, FAAH, FAAH2 HIF1A 928/4885MAPT 2156/4885PDE4A 1404/4885
US-10292967-B2 Compositions comprising corneoscleral tissue cross-linking agents SMCHD1, ALDH1A2, CRYAB HIF1A 916/4885MAPT 1897/4885PDE4A 2253/4885
US-20160374992-A1 COSMETIC PRESERVATIVES AS THERAPEUTIC CORNEOSCLERAL TISSUE CROSS-LINKING AGENTS COL1A1, COL14A1, COL2A1 HIF1A 859/4885MAPT 2942/4885PDE4A 1264/4885
US-12595238-B2 Process for producing hexahydro 1,3,5-trinitro-1,3,5-triazine and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine HAO2, TDO2, NT5C HIF1A 147/4885MAPT 2680/4885PDE4A 2439/4885
US-12617761-B2 Process for producing hexahydro 1,3,5-trinitro-1,3,5-triazine and octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine NT5C, TDO2, TH HIF1A 219/4885MAPT 3034/4885PDE4A 2550/4885
US-20120046246-A1 METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF CTSB, SOST, CTSG HIF1A 159/4885MAPT 3657/4885PDE4A 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.